Complete remission after pembrolizumab monotherapy in a non-small cell lung cancer patient with PD-L1 negative, high tumor mutational burden, and positive tumor-infiltrating lymphocytes: A case report
A comprehensive evaluation of multiple tumor biomarkers should be considered in NSCLC patients. Pembrolizumab monotherapy could benefit NSCLC patients with negative driver genes, PD-L1 negative, a high tumor mutational burden, and positive tumor-infiltrating lymphocytes.
Authors
- Jiequn Ma
- Suoni Li (ORCID: https://orcid.org/0000-0002-6174-5036)
- Zheng Zhao (ORCID: https://orcid.org/0000-0001-7068-1321)
- Jie Bai (ORCID: https://orcid.org/0000-0002-5735-4593)
Institutions
- Shanxi Medical University (CN)
- Shaanxi Provincial People's Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
Publication Details
- Journal
- Medicine
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1097/md.0000000000040369
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00